Ventana

The Ventana PD-L1 assay was approved as a complementary diagnostic for bladder cancer patients being considered for treatment with the immunotherapy Imfinzi. 

The companies are aiming to develop and commercialize a test to identify patients likely to respond to Loxo's cancer drug larotrectinib.

In October, Roche reported the tissue diagnostics business contributed 8 percent to diagnostics sales in the first nine months of 2016.

The agreement gives Ventana access to results from a collaboration and licensing agreement that Transgenomic made separately with the University of Melbourne.

Horizon will develop cell lines and associated derivative reference standard material for Ventana on a project-by-project basis.

The test may help identify patients most likely to respond to Roche's new metastatic urothelial cancer drug Tecentriq, the FDA said.

The non-small cell lung cancer drug now has two FDA-approved companion tests, Abbott's FISH test and Ventana's IHC test, for identifying patients most likely to benefit from treatment.

Ventana will develop an in vitro companion diagnostic assay to identify high levels of hyaluronan in metastatic pancreatic cancer patients.

The collaboration will focus initially on early-phase studies involving Astellas' FGFR inhibitor, dubbed ASP5878.

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.

In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.